drugset / Trial / NCT01844401

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

NCT01844401

Phase 1 Completed 15 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study is to compare the pharmacokinetic (PK) profiles of Albuterol Spiromax® and ProAir HFA after administration of a single inhaled dose of 180 mcg albuterol base from each product.

Timeline

Start
2013-04
Primary completion
2013-08
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 180 ug Inhaled

Indications